You are about to leave the Clinical Value website now.

Cancel

Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma

Quick Summary

Despite moderate sensitivity, alpha fetoprotein (AFP) is widely used in screening and prognostication for hepatocellular carcinoma (HCC). The objective of the current study was to assess clinical utility of Prothrombin induced by Vitamin K absence-II (PIVKA-II) in addition to AFP in patients with HCC.

 

244 patients with documented AFP, PIVKA-II and dynamic imaging of the liver were reviewed retrospectively. Using ROC curves, cutoff values for AFP and PIVKA-II for HCC detection, tumor grade and microvascular invasion (MVI) were assessed. In patients who underwent liver transplantation (LT) for HCC, survival was determined using Kaplan Meier curves.

You May Also Like

12 February 2026

LEAD Perspective: Evaluating GAAD – A Malaysian Multicentre Study

Read More
12 February 2026

LEAD Perspective: The Taiwan Liver Story – Hepatitis Elimination and HCC Surveillance

Read More
12 February 2026

LEAD Perspective: Asia Pacific Consensus Statement on the clinical and economic utility of biomarker-based algorithms in the early detection and surveillance of HCC

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.